The EU Patient-cEntric clinical tRial pLatforms, EU-PEARL project, aims to shape future drug development through a systematic approach that enables patient focused, cross company collaborative platform trials

EU-PEARL is a unique public-private strategic partnership focused on creating a framework to set up adaptive clinical trial platforms of the future

EU-PEARL hopes to transform clinical trials into a cross-company collaborative, multi-compound platform focused on patients

EU-PEARL will define a novel enabling infrastructure through an integrated system where pharmaceutical companies and healthcare providers can work together and integrated research platforms will become an obtainable alternative


Fundació Hospital Universitari Vall d'Hebrón – Institut de Recerca (Coordinator)ES
SYNAPSE Research Management Partners SLES
Medizinische Universitӓt WienAT
Katholieke Universiteit LeuvenBE
King’s College LondonUK
Universita Vita-Salute San RaffaeleIT
Erasmus Universitair Medisch Centrum RotterdamNL
Ludwig-Maximilians-Universitaet MuenchenDE
Charité - Universitaetsmedizin BerlinDE
Assistance Publique - Hôpitaux de ParisFR
Custodix NVBE
The European Institute for Innovation through Health DataBE
Berry Consultants LLPUK
ECRIN European Clinical Research Infrastructure NetworkFR
Forum Europeen des Patients (FPE)LU
University of Newcastle upon TyneUK
EUROSCAN International Network e.V.DE
Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische ArzneimittelDE
The Chancellor, Masters and Scholars of the University of OxfordUK
Università degli Studi di MilanoIT
DocuMental OÜEE
The University of ManchesterUK
Janssen Pharmaceutica NV (Project Leader)BE
Novartis Pharma AGUK
Allergan Limited UK
AstraZeneca ABSE
Novo Nordisk A/SDK
Otsuka Novel Products GmbHDE
Pfizer LimitedUK
Sanofi-Aventis Recherche & DeveloppementFR
Institut de Recherches Internationales ServierFR
Teva Pharmaceutical Industries LimitedIL
Children’s Tumor FoundationUS
SpringWorks TherapeuticsUS
Global Alliance for TB Drug Development non profit OrganisationUS


Funding period: 01/11/2019 to 30/04/2023. Years: 3.5 (2019-23)
EFPIA companies: 13. Academic & SMEs: 23
Total Budget: € 26 Million
IMI contribution: € 12 Million (in cash). EFPIA contribution: € 14 Million (in kind)
Project Coordinator: Fundació Hospital Universitari Vall D’Hebron – Institut de Recerca
Project Leader: Janssen Pharmaceutica NV


“EU-PEARL has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853966-2. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA”.

About IMI

he Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world's biggest public-private partnership (PPP) in the life sciences.


The EU-PEARL website reflects the author’s view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.